Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEARCA:GFINNASDAQ:KIN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGFINGoldman Sachs Finance Reimagined ETF$67.11+0.2%$67.11$38.81▼$68.70$52.01MN/A4,855 shs1,800 shsKINKindred Biosciences$9.25$9.22$3.46▼$9.28$420.52M1.3840,890 shs178,496 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGFINGoldman Sachs Finance Reimagined ETF0.00%0.00%0.00%0.00%0.00%KINKindred Biosciences0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGFINGoldman Sachs Finance Reimagined ETFN/AN/AN/AN/AN/AN/AN/AN/AKINKindred BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGFINGoldman Sachs Finance Reimagined ETF 0.00N/AN/AN/AKINKindred Biosciences 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGFINGoldman Sachs Finance Reimagined ETFN/AN/AN/AN/AN/AN/AKINKindred Biosciences$42.16M9.97N/AN/A$1.75 per share5.29Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGFINGoldman Sachs Finance Reimagined ETFN/AN/A0.00∞N/AN/AN/AN/AN/AKINKindred Biosciences-$21.80M-$0.55N/AN/AN/A-529.26%-54.19%-39.76%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGFINGoldman Sachs Finance Reimagined ETF$0.500.75%N/AN/AN/AKINKindred BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGFINGoldman Sachs Finance Reimagined ETFN/AN/AN/AKINKindred Biosciences0.197.027.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGFINGoldman Sachs Finance Reimagined ETFN/AKINKindred Biosciences66.89%Insider OwnershipCompanyInsider OwnershipGFINGoldman Sachs Finance Reimagined ETFN/AKINKindred Biosciences13.69%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGFINGoldman Sachs Finance Reimagined ETFN/A775,000N/ANot OptionableKINKindred Biosciences6345.46 millionN/AOptionableHRN, GFIN, INTO, and KIN HeadlinesRecent News About These CompaniesErnest MarioOctober 24, 2024 | centraljersey.comDuke Flags Lowered: Ernest Mario, Founding Chair of DUHS Board of Directors, DiesOctober 23, 2024 | today.duke.eduWhy Silicon Valley falls prey to ‘charisma distortion,’ according to investor and Google X founding member Tom ChiAugust 19, 2024 | msn.comWillow Smith announces the new release date of her first book “Black Shields Maiden”April 23, 2024 | msn.comExplosive Growth Projected in US Pet Medication Market, the Industry to Reach $17.90 Billion by 2029 - Exclusive Focus Insight Report by AriztonApril 2, 2024 | prnewswire.co.ukTory party donor Frank Hester to be investigated for 'racist comments' by West Yorkshire PoliceMarch 22, 2024 | mirror.co.ukNagaland Assembly passes resolution against Centre’s move to fence India-Myanmar borderMarch 2, 2024 | scroll.inKindred Hospital East GreensboroFebruary 23, 2024 | health.usnews.comJapan's Sony terminates $10 bln Zee India mergerJanuary 22, 2024 | reuters.comEuropean Shares Edge Higher With ECB Meeting In The SpotlightJanuary 22, 2024 | markets.businessinsider.comEarnings Optimism May Contribute To Continued Strength On Wall StreetJanuary 22, 2024 | markets.businessinsider.comAuthorities investigating garage fire in KindredDecember 28, 2023 | valleynewslive.comHonoree: Nanxi LiuDecember 17, 2023 | latimes.comStart-up Cradle tucks in $24m for protein engineering AINovember 29, 2023 | pharmaphorum.comStartup Cradle tucks in $24m for protein engineering AINovember 29, 2023 | pharmaphorum.comGlobal Companion Animal Pharmaceuticals Market Size To Worth USD 27.16 Billion by 2032 | CAGR of 5.7%November 8, 2023 | finance.yahoo.comMizoram Assembly elections: Incumbent MNF faces tough challenge; a look at key candidates and constituenciesNovember 6, 2023 | devdiscourse.comMat-Su Assembly member agrees to pay $77,500 for extending property into lake and wetlandsOctober 8, 2023 | adn.comKindred Hospital-DaytonOctober 7, 2023 | health.usnews.comBluejay Therapeutics expands management team and hired Christopher Holterhoff as senior Vice President, head of business developmentSeptember 21, 2023 | tmcnet.comTop HeadlinesView All HeadlinesTop 5 Stocks Hedge Funds Are Buying Right NowBy Ryan Hasson | May 20, 2025View Top 5 Stocks Hedge Funds Are Buying Right NowPalantir Scores First $1 Billion Contract; Is It Priced In?By Chris Markoch | May 27, 2025View Palantir Scores First $1 Billion Contract; Is It Priced In?3 Trades Members of Congress Are Making Right NowBy Chris Markoch | May 23, 2025View 3 Trades Members of Congress Are Making Right NowSMCI Stock Rally: 45% Gain in 2 Days Could Be Just the StartBy Thomas Hughes | May 14, 2025View SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the StartBest Value Stocks According to Morningstar in 2025By Gabriel Osorio-Mazilli | May 19, 2025View Best Value Stocks According to Morningstar in 2025HRN, GFIN, INTO, and KIN Company DescriptionsGoldman Sachs Finance Reimagined ETF NYSEARCA:GFIN$67.11 +0.14 (+0.21%) As of 11/6/2020Kindred Biosciences NASDAQ:KINKindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Microsoft's Outlook Brightens as Analysts Boost Bullish Ratings ThredUp Stock Reverses on AI Buzz, Eyes Double-Digit Gains Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
